Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Polyarticular Juvenile Idiopathic Arthritis (PJIA) Market Outlook

Thelansis’s “Polyarticular Juvenile Idiopathic Arthritis (PJIA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Polyarticular Juvenile Idiopathic Arthritis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Polyarticular Juvenile Idiopathic Arthritis (PJIA) Overview

Polyarticular Juvenile Idiopathic Arthritis (PJIA), a rare form of juvenile idiopathic arthritis, is characterized by the persistence of arthritis that begins before age 16 and affects at least five joints for more than six weeks within the first six months of onset. This subgroup can be divided into two categories: one with a positive rheumatoid factor (RF) test and the other with a negative RF test. The former requires at least two RF positive tests, spaced at least 3 months apart during the initial 6-month period. Both subgroups are more prevalent among girls and may present with mild fever, weight loss, anemia, moderate hepatosplenomegaly, and mild growth retardation. Children diagnosed with polyarticular JIA often face a more challenging disease course than those with fewer affected joints. Their prolonged active disease course increases their risk of joint damage, leading to poorer functional outcomes and reduced quality of life. Key indicators of a poor prognosis for polyarticular JIA, as outlined in the ACR recommendations for JIA, include the presence of positive RF antibodies, positive anti-CCP antibodies, hip arthritis, cervical spine arthritis, and the presence of erosions or joint space narrowing on radiographs. Additional factors linked to an unfavorable prognosis are early hand involvement and radiographic changes in carpal length within the first year of diagnosis. The primary goals of treatment are achieving disease remission, managing pain, and improving overall functioning. Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the most commonly prescribed medication for inflammatory arthritides, including JIA. NSAIDs work by inhibiting cyclooxygenase-1 and cyclooxygenase-2, thereby blocking prostaglandin formation and providing analgesic and anti-inflammatory effects.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: